Is Anti-CD19 CAR T Cell therapy an efficacious and tolerable option for refractory SLE?
NSMC intern Susan Thanabalasingam explains it graphically
This week, we will discuss the 2025 KDIGO IgAN guidelines. which the shift from supportive care to structured, evidence-based therapy
This week, we will discuss an old dilemma in nephrology. To restrict or supplement the proteins? Premise: advanced CKD and dialysis.
This week, we will discuss the use of creating chimeras to induce immune tolerance and its potential to decrease or eliminate the need for immunosuppression in kidney transplant recipients.
Is Anti-CD19 CAR T Cell therapy an efficacious and tolerable option for refractory SLE?
NSMC intern Susan Thanabalasingam explains it graphically
NSMC intern Sandhya Suresh simplifies the role of mRNA cis-inhibition in PKD progression via a lucid visual abstract
The ADVOR trial (adding acetazolamide in acute heart failure) is covered by #TenTweetNephJC
Welcome to #TenTweetNephJC
— Nephrology Jrnl Club (@NephJC) September 26, 2022
✳️ 10 tweet #NephJC catch-up ✳️
Did you ever think of using acetazolamide for acute congestive heart failure?
Read on to see whether we should or we should not! pic.twitter.com/e6XHi1JouG
The commentary on the BMJ meta-analysis on PLEX in ANCA vascuitis is now online on Kidney Medicine. Nice work by Anoushka Krishnan, Cristina Popa and Priyadarshini John. Read the paper here
The debate continues, but this time with cystatin-C measurements. Read the #TenTweetNephJC summary here!
Welcome to #TenTweetNephJC tweetorial
— Nephrology Jrnl Club (@NephJC) September 13, 2022
✳️ 10 tweets to catch-up with #NephJC ✳️
Have you ever prescribed piperacillin-tazobactam? Or avoided it due to fear of causing AKI?
Read on to learn more about the ‘nephrotoxin’ versus ‘pseudonephrotoxin’ debate pic.twitter.com/ZKX1ElhZds
Does acetazolamide help decongest in acute decompensated heart failure with volume overload? NSMC Intern Dr Api Chewcharat explains it with a beautiful visual abstract
Is Vancomycin/Piperacillin-tazobactam combination associated with higher rates of AKI?
Adeyemo Abiodun explains it beautifully with his visual abstract
And luckily this chat has another wonderful visual abstract by PS Vali.
Intravenous fluids in sepsis - not exactly a rare treatment in a niche condition. Rapidly catch-up on this weeks journal club at the link for the take-home points.
Welcome to #TenTweetNephJC
— Nephrology Jrnl Club (@NephJC) August 11, 2022
At journal club this week, a question that impacts all intensivists - when patients with septic shock need ongoing resuscitation after their initial 30cc/kg treatment, what strategy for intravenous fluid volume should we use?
Find out in thread👇 pic.twitter.com/z0pMmEp732